Next Article in Journal
Over 40 Years of Fosmidomycin Drug Research: A Comprehensive Review and Future Opportunities
Next Article in Special Issue
Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation of 18F-Labeled C-F and B-F Linkages
Previous Article in Journal
A Possible Explanation for the Low Penetrance of Pathogenic KCNE1 Variants in Long QT Syndrome Type 5
Previous Article in Special Issue
Fluorinated Protein and Peptide Materials for Biomedical Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 15
Issue 12
10.3390/ph15121552
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Communication

Facile Entry to Pharmaceutically Important 3-Difluoromethyl-quinoxalin-2-ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-ones

by
Kai-Zhong Fu
1,
Xu-Xin Chen
1,
Ya-Shi Zhao
1,
Yuan-Qing Gu
1 and
Guo-Kai Liu
1,2,*
1
School of Pharmaceutical Sciences, Shenzhen University Health Science Centre, Shenzhen University, Shenzhen 518060, China
2
Shenzhen Key Laboratory for Nano-Biosensing Technology, Shenzhen 518060, China
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2022, 15(12), 1552; https://doi.org/10.3390/ph15121552
Submission received: 9 November 2022 / Revised: 29 November 2022 / Accepted: 9 December 2022 / Published: 13 December 2022
(This article belongs to the Special Issue Fluorine-Containing Pharmaceuticals)
Browse Figures
Versions Notes

Abstract

:
CF2H moiety has a significant potential utility in drug design and discovery, and the incorporation of CF2H into biologically active molecules represents an important and efficient strategy for seeking lead compounds and drug candidates. On the other hand, quinoxalin-2-one is of great interest to pharmaceutical chemists as a common skeleton frequently occurring in plenty of natural products and bioactive compounds. Herein, we reported a practical and efficient protocol for the synthesis of 3-CF2H-quinoxalin-2-ones. Thus, in the presence of 3 mol% of photocatalyst and S-(difluoromethyl)sulfonium salt as difluoromethyl radical sources, a wide range of quinoxalin-2-ones readily underwent a visible-light redox-catalyzed difluoromethylation reaction, to deliver structurally diverse 3-difluoromethyl-quinoxalin-2-ones. We believe that this would facilitate increasing chances and possibilities for seeking potential lead compounds and drug candidates and further boost the development of fluorine-containing pharmaceuticals.

1. Introduction

The incorporation of fluorine and fluorinated moieties into organic molecules is of significant interest in drug design [1,2,3,4,5], agrochemicals [6,7,8], pharmaceuticals [9,10,11,12,13], and material science [14,15,16], due to the fact that fluorine can give the original molecules improved chemical, physical, and biological properties [2,10,17,18,19]. Particularly, thanks to an excellent lipophilicity, improved metabolic stability of fluorine-containing bioactive molecules that facilitates bioavailability, and better cell membrane permeability [2,3,19], it is becoming a routine tactic in new drug research and discovery to integrate fluorine or fluorine-containing structural motifs into bioactive molecules or lead compounds. As a result, the proportion of new molecule entities approved by the FDA has been higher and higher in recent years [20]. Notably, the difluoromethyl group (CF2H) is an important unit and plays a vital role in drug design and discovery, since CF2H can serve as a good hydrogen bond donor to enhance drug target affinity and target specificity as well as contribute to improved lipophilicity [21,22,23,24]. More importantly, the difluoromethyl group (CF2H) also constitutes a metabolically stable bioisosteres of alcohol, thiol, or amine groups, which are known to be three of the most common pharmacophores families in pharmaceuticals [3,25,26,27]. Subsequently, more and more pharmaceuticals and drug candidates bearing a CF2H structural motif have emerged over the past two decades (Figure 1).
On the other hand, quinoxalin-2-one is considered to be an important and prevalent structural skeleton, frequently existing in plenty of bioactive molecules and drugs and having a wide variety of biological activities such as antiviral, anti-inflammatory, antidiabetic, antimicrobial, and anticancer properties. Usually, modification on the C-3 position of quinoxalin-2-one is a common strategy to access structurally diverse quinoxalin-2-ones and leads to compounds with an improved biological activity. Moreover, in view of the significant potential of CF2H in pharmaceuticals, quinoxalin-2-ones decorated with CF2H at the C-3 position could provide more chances to seek lead molecules and drug candidates. Consequently, the difluoromethylation of quinoxalin-2-ones gradually aroused the interest of the synthetic chemistry and medicinal chemistry community in recent years. However, it remains a greatly challenging task to introduce a CF2H unit into quinoxalin-2-ones, despite the fact that a few approaches with a limited substrate scope were documented over the past few years [28,29,30]. As one part of our continuous efforts in developing difluoromethylating reagents and the application of their evaluation [31,32,33,34,35,36], we reported bench-stable electrophilic difluoromethylating reagents, S-(difluoromethyl)solfonium salts [31], which proved to be good difluoromethyl radical (·CF2H) reagents and readily yielded ·CF2H species to deliver a variety of radical transformations under photoredox catalytic conditions [35,36]. Very recently, we presented a one-pot process for the synthesis of 3-CF2H- quinoxalin-2-ones, enabled by the visible-light redox-catalyzed difluoromethylation of 1, 4-dihydro-quinoxalin-2-ones, following oxidation with DDQ (Scheme 1A) [37]. Hence, we question whether direct difluoromethylation of quinoxalin-2-ones could be achieved to easily access 3-CF2H-quinoxalin-2-ones. Consequently, herein, we report a more practical protocol for direct difluoromethylation of quinoxalin-2-ones (Scheme 1B).

2. Results and Discussions

Initially, we commenced our investigation by employing 1-methyl-quinoxalin-2-one 1aa as the model substrate and our difluoromethylating reagent 2 (2.0 equiv.) as a difluoromethyl radical source (·CF2H). To our delight, the reaction proceeded smoothly to afford the desired product, 3-CF2H-quinoxalin-2-one 3aa, in a 53% isolated yield under blue light irradiation in the presence of 3 mol % photosensitizer PCI and 2.0 equivalents of LiOH (Table 1, entry 1). Encouraged by this result, we further examined other commercially available photocatalysts, as shown in Table 1; Perylene offered a comparable result (entry 3), and the yield was not improved when employing 4CzIPN (entry 2), whereas the common organic photosensitizers Rose Bengal and Eosin Y were less effective for this transformation (entries 4,5). Ir-complex fac-Ir(ppy)3 and Ir(dFppy)3 were also effective photocatalysts, albeit offering lower yields of 39% and 41% (entries 6–7), respectively. We were delighted that PCII facilitated this reaction with a satisfied yield of 60% (entry 8), which proved to be the best one. Next, the effect of various bases on this reaction was surveyed; a wide variety of inorganic bases, including LiOH, LiOAc, tBuLi, K2CO3, and Na2CO3, can process this reaction to deliver the desired product, and LiOAc provided a comparable yield (entry 9). In contrast to inorganic bases, the organic base DIPEA did not work thoroughly (entry 13), probably due to its interaction with sulfonium salt 2. Additionally, screening of the solvent revealed that EtOAc was still the best one (entries 14–17 vs. 8), and aprotic polar solvent THF dramatically eroded this reaction, affording only a 24% yield (entry 17). Moreover, both increasing and decreasing reaction temperatures led to inferior results (entries 18, 19). Furthermore, the use of 5 mol% of PCII (entry 21) or prolonging the reaction time to 36 h (entry 20) did not further benefit the result. Predictably, both light and the photosensitizer were essential for this reaction, and no desired product was detected in the absence of each element (entries 22, 23).
To examine the generality of this method, we further explored the broad substrate’s scope to access structurally diverse 3-CF2H-quinoxaline-2-ones under the optimized reaction conditions or modified conditions (entry 8 in Table 1). As illustrated in Figure 2, the broad scope of substrates readily underwent this transformation to produce corresponding desired products in moderate to good yields. The tolerance of functional groups was investigated, and a wide range of functional groups, regardless of their electronic property, were compatible with this method, including F (3ab, 3aj, 3ar, 3bd), Cl (3ac, 3ak, 3as), Br (3ad, 3al, 3at), NO2 (3ae), CF3 (3af, 3an), CN (3ag, 3am), CO2Me (3ah, 3ao), tBu (3ai, 3ap), Me (3aq, 3au, 3bc), etc., providing corresponding desired products in moderate to good yields. Notably, in the case of 1ao, CH3CN was used as solvent instead of EtOAc to give 3ao in a 41% yield. Moreover, in many cases, three equivalents of reagent 2 and LiOH were used to gain better result, and four equivalents of reagent 2 and LiOH were necessary for 3af and 3at. Furthermore, the reaction was not sensible to a substituent position on the phenyl ring, and 5, 6, 7-substitutions were all well tolerated and exhibited a similar transformation efficiency (3ab-3ai vs. 3aj–3ap and 3aq). Remarkably, the reaction also worked well when employing di-substituted substrates, and di-F, di-Cl, di-Br and di-Me-quinoxaline-2-ones were transferred into corresponding desired products in good yields (3ar, 3as, 3at, 3au and 3bc, 3bd). Benzoquinoxalin-2-one 1aq was also shown to deliver 3aq when photocatalyst PC I was used instead of PC II, albeit in a lower isolated yield of 35%. The influence of protection groups on N1 was also examined. As a result, other alkyl groups, such as ethyl and n-butyl, were also compatible for delivering 3be and 3bf in good yields of 60% and 51%, respectively. Benzyl also proved to be a compatible N1-protection group, providing 3bb, 3bc and 3bd in good yields, regardless of electron-donating or electron-withdrawing group ornaments on the phenyl ring. Moreover, ketone and ester were also well-tolerant in this protocol and afforded 3bg–i in good yields. Interestingly, alkene and alkyne groups remained unreactive to giving the corresponding desired products under the standard conditions, at 36% (3bk) and 42% yields (3bl), respectively. Notably, N1-unprotected quinoxalin-2-one also efficiently processed this transformation, and 1ba readily converted to 3ba in a 55% yield using perylene as the photosensitizer. Finally, a large-scale transformation of 1aa (5.0 mmol) was demonstrated with a 47% isolated yield.
3-methyl-quinoxalin-2-mercapto-acetyl-urea 6, a vital quinoxaline-based, biologically active compound, exhibits significant potential as an inhibitor of Ebola and Marburg VP40 egress with low nM activity [38]. To further demonstrate the potential practicality of our approach, we conducted a rapid synthesis of 3-difluoromethyl-quinoxalin-2-mercapto-acetyl-urea 7 (Scheme 2), which might facilitate dramatically improved antiviral activity. Thus, difluoromethyl-functionalized compound 7 was readily accessed via three steps in a total yield of 75% from 3ba.
To reveal detailed insights into the mechanism of this transformation, several control experiments were carried out. The desired transformation was almost thoroughly depressed under the standard reaction conditions in the presence of radical inhibitor 1, 4-dinitrobenzene, and only a trace of 3aa was detected (Scheme 3A), indicating that a radical pathway is probably involved in the reaction. Moreover, a radical clock experiment was also explored, and thus the desired product 3aa was reduced to a 17% yield, while the rearranged product 9 from vinylcyclopropane 8 was isolated as the major product in a 26% yield (Scheme 3B). Consequently, the above experimental results clearly suggested that difluoromethyl radical species were involved in this transformation.
Based on these results from mechanistic experiments, a plausible reaction mechanism is proposed, as illustrated in Scheme 3C. Initially, difluoromethylating reagent 2 is reduced by the excited state PC* to deliver the CF2H radical and PC+; then, CF2H radical adds to quinoxalin-2-one 1, leading to intermediate nitrogen radical A, which undergoes single-electron oxidation by PC+ and a deprotonation process to render the desired product 3, along with the renewal of PC.

3. Materials and Methods

3.1. General Experimental Information

1H NMR spectra were recorded on either a Bruker Ascend 400 MHz spectrometer, a Bruker Ascend 500 MHz spectrometer or a Bruker Ascend 600 MHz spectrometer at ambient temperature unless otherwise indicated. Data were reported as follows: chemical shifts in ppm from tetramethylsilane as an internal standard in CDCl3 or DMSO-d6, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet-doublet, m = multiplet, br = broad), coupling constants (Hz), and assignment. 13C NMR spectra were recorded on either a Bruker Ascend 500 MHz(126 MHz) spectrometer, a Bruker Ascend 400 MHz (101 MHz) spectrometer or a Bruker Ascend 600 MHz (151 MHz) spectrometer at ambient temperature and were proton-decoupled. Chemical shifts are reported in ppm from tetramethylsilane on a scale with the solvent resonance employed as the internal standard. 19F NMR spectra were recorded on a Bruker Ascend 400 MHz (377 MHz) spectrometer or a Bruker Ascend 500 MHz (471 MHz) spectrometer at ambient temperature. Chemical shifts are reported in ppm from CFCl3 as the internal standard. ESI-MS analyses were performed in positive ionization mode on an Agilent 1260-Infinity LC/MSD resolution mass spectrometer. All high-resolution mass spectra were obtained on a Thermo Scientific Q-Exactive (HR/AM) Orbitrap mass spectrometer. Commercially available reagents were used as received. Reactions were monitored by TLC (detection with UV light). Flash chromatography: silica gel (300–400 mesh). Visible light irradiation was performed by Blue LED lamps (10 W; λ = 450 nm) for a preparative scale. Regent 2 was synthesized based on a reported procedure, and analytical data were consistent with those reported in the literature [31]. The NMR and mass data of all compounds are provided in the Supplementary Materials.

3.2. Reaction Apparatus

All reaction apparatus were illustrated in Figure 3 below.

3.3. Synthesis of Quinoxalin-2-Ones

All qunoxalin-2-ones are known and prepared according to these reported methods, and characteristic data are consistent with those reported in the literature. 1aa–1ab and 1ba–1bd [38], 1ac–1aq and 1be–1bl [39], 1ar–1av [40].

3.4. General Procedure for Visible-Light Redox-Catalyzed Difluoromethylation of Quinoxalin-2 ones

1-methylquinoxalin-2(1H)-one 1 (0.2 mmol, 1.0 equiv.), 2 (166.0 mg, 0.4 mmol, 2.0 equiv., or 0.6 mmol, 3.0 equiv., or 0.8 mmol, 4.0 equiv.), photocatalyst (4.4.mg, 0.006 mmol, 0.03 equiv. PCII, or PCI, or Perylene), LiOH (9.6 mg, 0.4 mmol, 2.0 equiv., or 0.6 mmol, 3.0 equiv., or 0.8 mmol, 4.0 equiv.) was added to a 20 mL quartz tube (quartz glass) equipped with a magnetic stir bar. Then, the flask was flushed with argon 3 times, followed by the addition of EtOAc (3 mL). The reaction mixture was stirred and irradiated using a 10 W 450 nm LED lamp (WATTCAS: WP-TEC-1020LC) at 25 °C for 18 h. Then, the reaction mixture was concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (petrol ether/dichloromethane/ethyl acetate) (Scheme 4).

3.5. Larger-Scale Experiment

A 200 mL flame-dried flask (Synthware Glass, Beijing F588100N) was charged with 1-methylquinoxalin-2(1H)-one 1aa (0.80 g, 5.0 mmol, 1.0 equiv), S-(difluoromethyl)sulfonium salt 2 (4.14 g, 10.0 mmol, 2.0 equiv), PCII (110.6 mg, 0.15 mmol, 0.03 equiv), and LiOH (242.0 mg, 10.0 mmol, 2.0 equiv.). The flask was evacuated and backfilled with argon 3 times, and then the solvent EtOAc was added by syringe (30 mL). The tube was placed at a distance of ~1 cm away from blue LED lamps (9 W × 4, λ = 450 nm), and the resulting reaction mixture was stirred under irradiation of blue LEDs at 25 °C for 18 h. The solvent was removed under reduced pressure. The residue was purified by flash column chromatography on silica gel (petrol ether/dichloromethane/ethyl acetate = 30:10:1) to give the desired product 3-(difluoromethyl)-1-methylquinoxalin-2(1H)-one (3aa) as a yellow solid (0.49 g, 47%) (Scheme 5).

3.6. Synthesis of 3-Difluoroemthyl-quinoxalin-2-thiol 5

Compound 5 was prepared using a modified method reported previously [41]: To a solution of difluoromethyl-1H-quinoxalin-2-one 3ba (120 mg, 0.612 mmol) in pyridine (10 mL), we added P2S5 (412.2 mg, 1.84 mmol). The resulting mixture was vigorously stirred at 80 °C for 3 days. Then, the resulting reaction mixture was cooled to room temperature, and 50 mL water was added and extracted with EtOAc (4 × 50 mL). The combined organic layers were washed with brine (3 × 50 mL) and dried over Na2SO4. The filtration was concentrated under reduced pressure, and the crude was recrystallized from dichloromethane and petrol ether to give 105 mg (81%) 5 as a bright yellow solid (Scheme 6).

3.7. Synthesis of 1-(2-Chloroacetyl)-3-(2-methylphenyl)-urea 4

Compound 4 was prepared using a modified method reported previously [41]: 2-Chloroacetylisocyanate (250 mg, 2 mmol) was added to a solution of 2-methylaniline (107 mg, 1 mmol) in DCM (5 mL) at room temperature. The resulting reaction mixture was stirred overnight and then concentrated in vacuo, and the residue was recrystallized from dichloromethane and petrol ether to give 287 mg 4 (quantitative yield) as a brown solid (Scheme 7).

3.8. Synthesis of 1-(2-Methylphenyl)-3-[2-(3-difluoromethyl-quinoxalin-2-ylsulfanyl)-acetyl]-urea 7

Compound 7 was prepared using a modified method reported previously [41]: 3-Difluoromethyl-quinoxaline-2-thiol 5 (50 mg, 0.24 mmol), 1-(2-chloroacetyl)-3-(2-methylphenyl)-urea 4 (54.4 mg, 0.24 mmol), and sodium acetate (29.8 mg, 0.36 mol) were added to 5 mL EtOH, and the resulting mixture was heated to 80 °C and reacted overnight. The solvent was removed under reduced pressure, and the crude was recrystallized from CH2Cl2 and petrol ether, affording 90 mg 7 (93% yield) as an off-white solid (Scheme 8).

3.9. Radical Trapping Experiment

The reaction was conducted under standard reaction conditions (see 3.4 above) with the addition of 1,4-dinitrobenzene (67.2 mg, 0.4 mmol, 2.0 equiv.). Additionally, the reaction mixture was monitored by 19F NMR using PhF (0.2 mmol) as the internal standard, and only a trace of 3aa was detected (Scheme 9).

3.10. Radical-Clock Experiment

The reaction was conducted under the standard reaction conditions (see 3.4 above) with the addition of 1-chloro-4-(1-cyclopropylvinyl)benzene 8 (36.0 mg, 0.2 mmol, 1.0 equiv.). The residue was purified by flash column chromatography on silica gel with petrol ether (9) and petrol ether/dichloromethane/ethyl acetate (3aa) to afford 11.8 mg 9 (26%) as a colorless oil and 7.0 mg 3aa (17%), respectively (Scheme 10).

4. Conclusions

In conclusion, we have developed a facile approach for the direct difluoromethylation of quinoxalin-2-ones using electrophilic difluoromethylating reagent 2 as a difluoromethyl source. In the presence of 3 mol % photocatalyst, the reaction readily proceeded under visible light irradiation at room temperature, displaying a broad substrate scope and functional group tolerance and enabling access to a wide variety of 3-CF2H-quinoxalin-2-ones in moderate-to-good yields. Notably, these described products are of great interest to the pharmaceutical chemistry community and show great potential for the development of fluorine-containing drugs. Remarkably, a rapid synthesis of difluoromethylated derivative 7 from a pharmacologically antiviral agent was readily achieved. Furthermore, the reaction mechanism was also studied, and a rational pathway involving difluoromethyl radical species was proposed.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/ph15121552/s1; Supplementary Materials is the NMR and mass data of compounds (Figure S1–S74).

Author Contributions

Conceptualization G.-K.L.; investigation, K.-Z.F. and X.-X.C.; data curation, K.-Z.F.; preparation of reagent 2, Y.-S.Z. and Y.-Q.G.; writing—original draft preparation, G.-K.L.; writing—review and editing, G.-K.L.; supervision, G.-K.L.; funding acquisition, G.-K.L. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Natural Science Foundation of China (NSFC), grant number 92056201.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and the Supplementary Materials.

Acknowledgments

The authors thank the Instrumental Analysis Center of Shenzhen University for analytical work.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Purser, S.; Moore, P.R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320–330. [Google Scholar] [CrossRef] [PubMed]
  2. Hagmann, W.K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008, 51, 4359–4369. [Google Scholar] [CrossRef] [PubMed]
  3. Ojima, I. Fluorine in Medicinal Chemistry and Chemical Biology; Wiley-Blackwell: Chichester, UK, 2009. [Google Scholar]
  4. Gillis, E.P.; Eastman, K.J.; Hill, M.D.; Donnelly, D.J.; Meanwell, N.A. Applications of fluorine in medicinal chemistry. J. Med. Chem. 2015, 58, 8315–8359. [Google Scholar] [CrossRef] [PubMed]
  5. Swallow, S. Fluorine in medicinal chemistry. Prog. Med. Chem. 2015, 54, 65–133. [Google Scholar] [PubMed]
  6. Goure, W.F.; Leschinsky, K.L.; Wratten, S.J.; Chupp, J.P. Synthesis and herbicidal activity of N-substituted 2,6-bis(polyfluoromethyl)dihydropyridine-3,5-dicarboxylates. J. Agric. Food Chem. 1991, 39, 981–986. [Google Scholar] [CrossRef]
  7. Jeschke, P. The Unique Role of Fluorine in the Design of Active Ingredients for Modern Crop Protection. ChemBioChem 2004, 5, 570–589. [Google Scholar] [CrossRef]
  8. Ogawa, Y.; Tokunaga, E.; Kobayashi, O.; Hirai, K.; Shibata, N. Current contributions of organofluorine compounds to the agrochemical industry. iScience 2020, 23, 101467. [Google Scholar] [CrossRef]
  9. Isanbor, C.; O’Hagan, D. Fluorine in Medicinal Chemistry: A Review of Anti-Cancer Agents. J. Fluor. Chem. 2006, 127, 303–319. [Google Scholar] [CrossRef]
  10. MÜller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: Looking beyond Intuition. Science 2007, 317, 1881–1886. [Google Scholar] [CrossRef] [Green Version]
  11. Gouverneur, V.; Muller, K. Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications; Imperial College Press: London, UK, 2012. [Google Scholar]
  12. Wang, J.; Sanchez-Rosello, M.; Acena, J.L.; del Pozo, C.; Sorochinsky, A.E.; Fustero, S.; Soloshonok, V.A.; Liu, H. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). Chem. Rev. 2014, 114, 2432–2506. [Google Scholar] [CrossRef]
  13. Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J.L.; Soloshonok, V.A.; Izawa, K.; Liu, H. Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: New structural trends and therapeutic areas. Chem. Rev. 2016, 116, 422–518. [Google Scholar] [CrossRef] [PubMed]
  14. Kirsch, P.; Bremer, M. Nematic liquid crystals for active matrix displays: Molecular design and synthesis. Angew. Chem. Int. Ed. 2000, 39, 4216–4235. [Google Scholar] [CrossRef]
  15. Tasaka, T.; Takenaka, S.; Kabu, K.; Morita, Y.; Okamoto, H. Smectic phase exhibited by dissymmetric liquid crystals: Effect of a terminal fluoromethyl group on mesomorphic properties. Ferroelectronics 2002, 276, 83–92. [Google Scholar] [CrossRef]
  16. Boltalina, O.V.; Nakajima, T. New Fluorinated Carbons: Fundamentals and Applications; Elsevier: Amsterdam, The Netherlands, 2016. [Google Scholar]
  17. Banks, R.E.; Smart, B.E.; Tatlow, J.C. (Eds.) Organofluorine Chemistry, Principles and Applications; Plenum: New York, NY, USA, 1994. [Google Scholar]
  18. Kirsch, P. Modern Fluoroorganic Chemistry: Synthesis, Reactivity, Applications, 2nd ed.; Wiley-VCH: Weinheim, Germany, 2013. [Google Scholar]
  19. Meanwell, N.A. Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design. J. Med. Chem. 2018, 61, 5822–5880. [Google Scholar] [CrossRef]
  20. Available online: https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (accessed on 1 December 2022).
  21. Erickson, J.A.; McLoughlin, J.I. Hydrogen Bond Donor Properties of the Difluoromethyl Group. J. Org. Chem. 1995, 60, 1626–1631. [Google Scholar] [CrossRef]
  22. Sessler, C.D.; Rahm, M.; Becker, S.; Goldberg, J.M.; Wang, F.; Lippard, S.J. CF2H, a Hydrogen Bond Donor. J. Am. Chem. Soc. 2017, 139, 9325–9332. [Google Scholar] [CrossRef]
  23. Zafrani, Y.; Yeffet, D.; Sod-Moriah, G.; Berliner, A.; Amir, D.; Marciano, D.; Gershonov, E.; Saphier, S. Difluoromethyl Bioisostere: Examining the “Lipophilic Hydrogen Bond Donor” Concept. J. Med. Chem. 2017, 60, 797–804. [Google Scholar] [CrossRef]
  24. Zafrani, Y.; Sod-Moriah, G.; Yeffet, D.; Berliner, A.; Amir, D.; Marciano, D.; Elias, S.; Katalan, S.; Ashkenazi, N.; Madmon, M.; et al. CF2H, a Functional Group-Dependent Hydrogen-Bond Donor: Is It a More or Less Lipophilic Bioisostere of OH, SH, and CH3? J. Med. Chem. 2019, 62, 5628–5637. [Google Scholar] [CrossRef]
  25. Meanwell, N.A. Synopsis of some recent tactical application of bioisosteres in drug design. J. Med. Chem. 2011, 54, 2529–2591. [Google Scholar] [CrossRef]
  26. Martínez, M.D.; Luna, L.; Tesio, A.Y.; Feresin, G.E.; Durán, F.J.; Burton, G. Antioxidant properties in a nonpolar environment of difluoromethyl bioisosteres of methylhydroxycinnamates. J. Pharm. Pharmacol. 2016, 68, 233–244. [Google Scholar] [CrossRef]
  27. Rodriguez, C.R.; del Fueyo, M.C.; Santillán, V.J.; Virginia, D.M.; Veleiro, A.S.; Castro, O.A.; Burton, G. Synthesis and biological activity of fluorinated analogues of the DAF-12 receptor antagonist 24-hydroxy-4-cholen-3-one. Steroids 2019, 151, 108469. [Google Scholar] [CrossRef] [PubMed]
  28. Zhang, W.; Xiang, X.-X.; Chen, J.; Yang, C.; Pan, Y.-L.; Cheng, J.-P.; Meng, Q.; Li, X. Direct C-H difluoromethylation of hetercycles via organic photoredox catalysis. Nat. Commun. 2020, 11, 638. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Yang, J.; Zhu, S.; Wang, F.; Qing, F.-L.; Chu, L. Silver-Enabled General Radical Difluoromethylation Reaction with TMSCF2H. Angew. Chem. Int. Ed. 2021, 60, 4300–4306. [Google Scholar] [CrossRef] [PubMed]
  30. Dai, P.; Li, C.; Li, Y.; Zhu, Y.; Teng, P.; Gu, Y.-C.; Zhang, W.-H. Direct Difluoromethylation of Heterocycles through Photosensitized Electron Transfer. Eur. J. Org. Chem. 2022, 2022, e202100896. [Google Scholar] [CrossRef]
  31. Lu, S.-L.; Li, X.; Qin, W.-B.; Liu, J.-J.; Huang, Y.-Y.; Wong, H.N.C.; Liu, G.-K. Air- and Light-Stable S-(Difluoromethyl)Sulfonium Salts: C-Selective Electrophilic Difluoromethylation of β-Ketoesters and Malonates. Org. Lett. 2018, 20, 6925–6929. [Google Scholar] [CrossRef] [PubMed]
  32. Liu, G.-K.; Li, X.; Qin, W.-B.; Peng, X.-S.; Wong, H.N.C.; Zhang, L.; Zhang, X. Facile Difluoromethylation of Aliphatic Alcohols with an S-(Difluoro-methyl)Sulfonium Salt: Reaction, Scope and Mechanistic Study. Chem. Commun. 2019, 55, 7446–7449. [Google Scholar] [CrossRef] [PubMed]
  33. Liu, G.-K.; Qin, W.-B.; Li, X.; Lin, L.-T.; Wong, H.N.C. Difluoromethylation of Phenols and Thiophenols with the S-(Difluoromethyl)Sulfonium Salt: Reaction, Scope, and Mechanistic Study. J. Org. Chem. 2019, 84, 15948–15957. [Google Scholar] [CrossRef]
  34. Liu, G.-K.; Li, X.; Qin, W.-B.; Lin, W.-F.; Lin, L.-T.; Chen, J.-Y.; Liu, J.-J. Selective O-Difluoromethylation of 1,3-Diones Using S-(Difluoromethyl)-Sulfonium Salt. Chin. Chem. Lett. 2019, 30, 1515–1518. [Google Scholar] [CrossRef]
  35. Qin, W.-B.; Xiong, W.; Li, X.; Chen, J.-Y.; Lin, L.-T.; Wong, H.N.C.; Liu, G.-K. Visible-Light-Driven Difluoromethylation of Isocyanides with S-(Difluoromethyl)Diarylsulfonium Salt: Access to a Wide Variety of Difluoromethylated Phenanthridines and Isoquinolines. J. Org. Chem. 2020, 85, 10479–10487. [Google Scholar] [CrossRef]
  36. Qin, W.-B.; Xiong, W.; Zhao, Y.-S.; Fu, K.-Z.; Su, L.; Liu, G.-K. Difluoromethyl radical triggered tandem reaction of N-Allylamides to difluoromethylated β-amino alcohols by photoredox catalysis. Org. Lett. 2021, 23, 8482–8487. [Google Scholar] [CrossRef]
  37. Xiong, W.; Qin, W.-B.; Zhao, Y.-S.; Fu, K.-Z.; Liu, G.-K. Direct C(sp3)–H difluoromethylation via radical–radical cross-coupling by visible-light photoredox catalysis. Org. Chem. Front. 2022, 9, 2141–2148. [Google Scholar] [CrossRef]
  38. Chen, D.; Wang, Z.J.; Bao, W. Copper-catalyzed cascade syntheses of 2H-benzo[b][1,4]thiazin-3(4H)-ones and quinoxalin-2(1H)-ones through capturing S and N atom respectively from AcSH and TsNH2. J. Org. Chem. 2010, 75, 5768–5771. [Google Scholar] [CrossRef] [PubMed]
  39. Aoki, K.; Obata, T.; Yamazaki, Y.; Mori, Y.; Hirokawa, H.; Koseki, J.-I.; Hattori, T.; Niitsu, K.; Takeda, S.; Aburada, M.; et al. Potent Platelet-Derived Growth Factor-b Receptor (PDGF-bR) Inhibitors: Synthesis and Structure–Activity Relationships of 7-[3-(Cyclohexylmethyl)ureido]-3-{1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl}quinoxalin-2(1H)-one Derivatives. Chem. Pharm. Bull. 2007, 55, 255–267. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Jacobsen, E.J.; TenBrink, R.E.; Stelzer, L.S.; Belonga, K.L.; Carter, D.B.; Im, H.K.; Im, W.B.; Sethy, V.H.; Tang, A.H.; VonVoigtlander, P.F.; et al. High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex. J. Med. Chem. 1996, 39, 158–175. [Google Scholar] [CrossRef]
  41. Marie Loughran, H.; Han, Z.; Wrobel, J.E.; Decker, S.E.; Ruthel, G.; Freedman, B.D.; Harty, R.N.; Reitz Allen, B. Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. Bioorg. Med. Chem. Lett. 2016, 26, 3429–3435. [Google Scholar] [CrossRef]
Pharmaceuticals 15 01552 g001 550
Figure 1. Selected examples of CF2H-containing pharmaceuticals and drug candidates over the past two decades.
Figure 1. Selected examples of CF2H-containing pharmaceuticals and drug candidates over the past two decades.
Pharmaceuticals 15 01552 g001
Pharmaceuticals 15 01552 sch001 550
Scheme 1. Synthesis of 3-CF2H-quinoxalin-2-ones. (A) A one-pot process for the synthesis of 3-CF2H- quinoxalin-2-ones, enabled by the visible-light redox-catalyzed difluoromethylation of 1, 4-dihydro-quinoxalin-2-ones, following oxidation with DDQ. (B)Protocol for direct difluoromethylation of quinoxalin-2-ones.
Scheme 1. Synthesis of 3-CF2H-quinoxalin-2-ones. (A) A one-pot process for the synthesis of 3-CF2H- quinoxalin-2-ones, enabled by the visible-light redox-catalyzed difluoromethylation of 1, 4-dihydro-quinoxalin-2-ones, following oxidation with DDQ. (B)Protocol for direct difluoromethylation of quinoxalin-2-ones.
Pharmaceuticals 15 01552 sch001
Pharmaceuticals 15 01552 g002 550
Figure 2. Scope of visible-light-induced difluoromethylation of quinoxalin-2-ones 1.1 Reaction conditions (unless otherwise specified): 1 (0.2 mmol, 1.0 equiv.), PC II (3 mol%), reagent 2 (0.4 mmol, 2.0 equiv.), LiOH (0.4 mmol, 2.0 equiv.), EtOAc(3.0 mL), 25 °C, overnight (18 h). Isolated yields. 2 large scale (5 mmol) reaction. 3 3 equiv. of reagent 2 and LiOH were used. 4 4 equiv. of reagent 2 and LiOH were used. 5 CH3CN was used as solvent. 6 PC I was used as photocatalyst. 7 Perylene used as photocatalyst.
Figure 2. Scope of visible-light-induced difluoromethylation of quinoxalin-2-ones 1.1 Reaction conditions (unless otherwise specified): 1 (0.2 mmol, 1.0 equiv.), PC II (3 mol%), reagent 2 (0.4 mmol, 2.0 equiv.), LiOH (0.4 mmol, 2.0 equiv.), EtOAc(3.0 mL), 25 °C, overnight (18 h). Isolated yields. 2 large scale (5 mmol) reaction. 3 3 equiv. of reagent 2 and LiOH were used. 4 4 equiv. of reagent 2 and LiOH were used. 5 CH3CN was used as solvent. 6 PC I was used as photocatalyst. 7 Perylene used as photocatalyst.
Pharmaceuticals 15 01552 g002
Pharmaceuticals 15 01552 sch002 550
Scheme 2. Synthesis of 3-CF2H-quinoxalin-2-mercapto-acetyl-urea.
Scheme 2. Synthesis of 3-CF2H-quinoxalin-2-mercapto-acetyl-urea.
Pharmaceuticals 15 01552 sch002
Pharmaceuticals 15 01552 sch003 550
Scheme 3. Mechanistic studies and proposed mechanism. (A) Evidence of difluoromethyl radical species (B)Radical – clock experiment (C) Proposed mechanism.
Scheme 3. Mechanistic studies and proposed mechanism. (A) Evidence of difluoromethyl radical species (B)Radical – clock experiment (C) Proposed mechanism.
Pharmaceuticals 15 01552 sch003
Pharmaceuticals 15 01552 g003 550
Figure 3. Reaction apparatus.
Figure 3. Reaction apparatus.
Pharmaceuticals 15 01552 g003
Pharmaceuticals 15 01552 sch004 550
Scheme 4. General reaction procedure.
Scheme 4. General reaction procedure.
Pharmaceuticals 15 01552 sch004
Pharmaceuticals 15 01552 sch005 550
Scheme 5. Larger-scale experiment.
Scheme 5. Larger-scale experiment.
Pharmaceuticals 15 01552 sch005
Pharmaceuticals 15 01552 sch006 550
Scheme 6. Synthesis of 5.
Scheme 6. Synthesis of 5.
Pharmaceuticals 15 01552 sch006
Pharmaceuticals 15 01552 sch007 550
Scheme 7. Synthesis of 4.
Scheme 7. Synthesis of 4.
Pharmaceuticals 15 01552 sch007
Pharmaceuticals 15 01552 sch008 550
Scheme 8. Synthesis of 7.
Scheme 8. Synthesis of 7.
Pharmaceuticals 15 01552 sch008
Pharmaceuticals 15 01552 sch009 550
Scheme 9. Radical trapping experiment.
Scheme 9. Radical trapping experiment.
Pharmaceuticals 15 01552 sch009
Pharmaceuticals 15 01552 sch010 550
Scheme 10. Radical-clock experiment.
Scheme 10. Radical-clock experiment.
Pharmaceuticals 15 01552 sch010
Table
Table 1. Optimization of conditions 1.
Table 1. Optimization of conditions 1.
Pharmaceuticals 15 01552 i001
EntryPCBaseTemp. (℃)SolventYield (%)
1PC ILiOH25 °CAcOEt53
24CzIPNLiOH25 °CAcOEt35
3PeryleneLiOH25 °CAcOEt52
4Rose BengalLiOH25 °CAcOEtNR
5Eosin Y LiOH25 °CAcOEttrace
6fac-Ir(ppy)3LiOH25 °CAcOEt39
7Ir(dFppy)3LiOH25 °CAcOEt41
8PC IILiOH25 °CAcOEt60
9PC IILiOAc25 °CAcOEt58
10PC IItBuOLi25 °CAcOEt46
11PC IIK2CO325 °CAcOEt36
12PC IINa2CO325 °CAcOEt24
13PC IIDIPEA25 °CAcOEtNR
14PC IILiOH25 °CDCM56
15PC IILiOH25 °CCHCl345
16PC IILiOH25 °CCH3CN45
17PC IILiOH25 °CTHF24
18PC IILiOH40 °CAcOEt51
19PC IILiOH0 °CAcOEt43
20 2PC IILiOH25 °CAcOEt60
21 3PC II (5 mol%)LiOH25 °CAcOEt57
22 4PC II/no lightLiOH25 °CAcOEtNR
23 5no PC IILiOH25 °CAcOEtNR
1 Reaction conditions (unless otherwise specified): 1aa (0.2 mmol, 1.0 equiv.), photocatalyst (3 mol%), reagent 2 (0.4 mmol, 2.0 equiv.), base (0.4 mmol, 2.0 equiv.), solvent (3.0 mL), 25 °C, overnight (18 h). Isolated yields. 2 Reaction time was prolonged to 36 h. 3 5 mol% photocatalyst was used. 4 No blue light irradiation. 5 No photocatalyst.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Fu, K.-Z.; Chen, X.-X.; Zhao, Y.-S.; Gu, Y.-Q.; Liu, G.-K. Facile Entry to Pharmaceutically Important 3-Difluoromethyl-quinoxalin-2-ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-ones. Pharmaceuticals 2022, 15, 1552. https://doi.org/10.3390/ph15121552

AMA Style

Fu K-Z, Chen X-X, Zhao Y-S, Gu Y-Q, Liu G-K. Facile Entry to Pharmaceutically Important 3-Difluoromethyl-quinoxalin-2-ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-ones. Pharmaceuticals. 2022; 15(12):1552. https://doi.org/10.3390/ph15121552

Chicago/Turabian Style

Fu, Kai-Zhong, Xu-Xin Chen, Ya-Shi Zhao, Yuan-Qing Gu, and Guo-Kai Liu. 2022. "Facile Entry to Pharmaceutically Important 3-Difluoromethyl-quinoxalin-2-ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-ones" Pharmaceuticals 15, no. 12: 1552. https://doi.org/10.3390/ph15121552

APA Style

Fu, K. -Z., Chen, X. -X., Zhao, Y. -S., Gu, Y. -Q., & Liu, G. -K. (2022). Facile Entry to Pharmaceutically Important 3-Difluoromethyl-quinoxalin-2-ones Enabled by Visible-Light-Driven Difluoromethylation of Quinoxalin-2-ones. Pharmaceuticals, 15(12), 1552. https://doi.org/10.3390/ph15121552

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop